Abstract
The use of immunohistochemistry (IHC) and molecular pathology has been widely adopted over the past 3 decades and has aided in the precision of diagnosing gynecologic tumors. While many tumors can be diagnosed by histologic appearance on routine hematoxylin and eosin stained slides, the use of IHC has dramatically changed practice, leading to a better understanding and subtyping of gynecologic tumors. This detailed classification of tumors has aided in the implementation and development of targeted therapies. Available IHC stains and their applications continue to rapidly evolve. Our review aims to provide updated information on the use of IHC in gynecologic tumors. We will also address the rationale for preferred therapeutic regimens that are personalized based on IHC.